BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 8, 2018--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will participate in the 7th Annual Glaucoma
360 New Horizons Forum being held on Friday, February 9, 2018, at The
Palace Hotel, in San Francisco. This meeting presented by Glaucoma
Research Foundation brings together key clinical, industry, financial
and regulatory leaders in a unique exchange on research innovation and
advances in glaucoma treatment. Globally, glaucoma is a leading cause of
preventable blindness.
Michael Goldstein, MD, Chief Medical Officer of Ocular Therapeutix, will
present on Friday, February 9, 2018 at 1:45 p.m. PST. The title of the
presentation will be “Transforming Glaucoma Care with Sustained
Therapies,” and will focus on Ocular Therapeutix’s glaucoma programs and
also cover other product candidates in the Company pipeline that use the
Company’s proprietary hydrogel formulation platform.
Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew Iwach, MD,
who serve on the Glaucoma Research Foundation Board of Directors. Drs.
Graves and Iwach also serve as Co-Chairs for the Glaucoma 360 New
Horizons Forum.
Dr. Iwach, GRF Board Chair and Executive Director at the Glaucoma Center
of San Francisco, said, “Glaucoma 360 is designed to bring greater
awareness to unmet medical needs in glaucoma and to highlight current
and novel therapies that will help preserve sight for patients with
glaucoma.”
About Glaucoma Research Foundation
Founded in 1978 and headquartered in San Francisco, Glaucoma Research
Foundation is America’s oldest and most experienced nonprofit
organization dedicated solely to its mission: to prevent vision loss
from glaucoma by investing in innovative research, education and support
with the ultimate goal of finding a cure.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
hydrogel-based formulation technology. Ocular Therapeutix’s lead product
candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular
use, has completed Phase 3 clinical development for the treatment of
ocular pain and inflammation following ophthalmic surgery. OTX-TP
(travoprost insert) is in Phase 3 clinical development for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral injection for the reduction in
intraocular pressure in patients with glaucoma and ocular hypertension,
as well as sustained release intravitreal injections for the treatment
of retinal diseases. These injections include the development of
OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with
Regeneron, an extended release protein-based anti-vascular endothelial
growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company,
including the development and regulatory status of the Company’s product
candidates, such as the Company’s regulatory submissions for and the
timing and conduct of, or implications of results from, clinical trials
of DEXTENZA™ for the treatment of post-surgical ocular inflammation and
pain, including with respect to manufacturing deficiencies identified by
the Food and Drug Administration (FDA), the Company’s expectations
regarding resubmitting its NDA to the FDA and the prospects for
approvability of DEXTENZA for these indications, DEXTENZA for the
treatment of allergic conjunctivitis, DEXTENZA for the treatment of dry
eye disease and OTX-TP for the treatment of glaucoma and ocular
hypertension, the ongoing development of the Company’s sustained release
hydrogel depot technology, the potential utility of any of the Company’s
product candidates, potential commercialization of the Company’s product
candidates, the potential benefits and future operation of the
collaboration with Regeneron Pharmaceuticals, including any potential
future payments thereunder, the sufficiency of the Company’s cash
resources and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that
receives regulatory approval, the initiation and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources, the outcome of the Company’s ongoing legal proceedings and
need for additional financing or other actions and other factors
discussed in the “Risk Factors” section contained in the Company’s
quarterly and annual reports on file with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this
press release represent the Company’s views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208005677/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke
Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
or
Media
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com
